首页> 外国专利> NEUROENDOCRINE CANCER TARGETED THERAPY

NEUROENDOCRINE CANCER TARGETED THERAPY

机译:神经内分泌癌靶向治疗

摘要

A majority of neuroendocrine (NE) cancers overexpress somatostatin receptors (SSTRs). Disclosed herein are anti-SSTR2 monoclonal antibodies, and antibody-drug conjugates (ADCs) for use as NE cancer targeting therapeutics. Also disclosed is an isolated nucleic acid encoding the disclosed antibodies, as well as nucleic acid vectors containing this isolated nucleic acid operably linked to an expression control sequence. Also disclosed are cells transfected with these vectors and the use of these cells to produce the disclosed recombinant antibodies. Also disclosed is a method of treating a neuroendocrine (NE) cancer in a subject, comprising administering to the subject an effective amount of the disclosed antibody conjugated to an anti-cancer agent.
机译:大多数神经内分泌(NE)癌症过表达生长抑素受体(SSTR)。 本文公开了抗SSTR2单克隆抗体,以及抗体 - 药物缀合物(ADC),其用作靶向治疗剂的NE癌症。 还公开了编码所公开的抗体的分离的核酸,以及含有与表达控制序列可操作地连接的该分离的核酸的核酸载体。 还公开了用这些载体转染的细胞和使用这些细胞以产生所公开的重组抗体。 还公开了一种在受试者中治疗神经内分泌(NE)癌症的方法,包括向受试者施用与抗癌剂缀合的所公开的抗体。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号